FDA v. Wages and White Lion Investments, L.L.C.
| FDA v. Wages and White Lion Investments, L.L.C. | |
|---|---|
| Argued December 2, 2024 Decided April 2, 2025 | |
| Full case name | Food and Drug Administration v. Wages and White Lion Investments, L.L.C., dba Triton Distribution, et al. |
| Docket no. | 23-1038 |
| Citations | 604 U.S. ___ (more) |
| Argument | Oral argument |
| Decision | Opinion |
| Case history | |
| Prior | Stay pending review granted, 16 F.4th 1130 (5th Cir. 2021); petitions for review denied, 41 F.4th 427 (5th Cir. 2022); FDA denial orders set aside, 90 F.4th 357 (5th Cir. 2024) (en banc); cert. granted (July 2, 2024) |
| Holding | |
| The FDA's denial of authorization to market flavored electronic cigarettes was not arbitrary and capricious | |
| Court membership | |
| |
| Case opinions | |
| Majority | Alito, joined by unanimous |
| Concurrence | Sotomayor |
| Laws applied | |
| Administrative Procedure Act | |
FDA v. Wages and White Lion Investments, L.L.C., 604 U.S. ___ (2025), is a United States Supreme Court decision holding that the Food and Drug Administration's denial of authorization to market flavored electronic cigarette products was not arbitrary and capricious under the Administrative Procedure Act (APA).